Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07679789

Community-acquired Pneumonia Due to Chlamydia Pneumoniae

This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.

The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.

The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.

Secondary objectives include;

1. Outpatient management 2. Hospitalization in a medical ward 3. Admission to the intensive care unit 4. In-hospital mortality 5. Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6. Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing. Secondary objectives include;1)Outpatient management2)Hospitalization in a medical ward3)Admission to the intensive care unit4) In-hospital mortality5) Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6)Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP

Detailed Description We have all learned and continue to teach that community-acquired pneumonia (CAP) is essentially represented by three bacteria: Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae. While the recent Mycoplasma outbreak in France and the prevalence of severe Legionella infections in intensive care units confirm the real impact of these pathogens in CAP, the low number of Chlamydia pneumoniae cases documented by PCR raises questions.Over the past twenty years, the development of highly sensitive molecular tests (specific PCR or multiplex PCR targeting intracellular respiratory pathogens) has made it possible to precisely detect Chlamydia pneumoniae and to confirm or rule out its presence in the respiratory tract of patients with pneumonia.We are therefore conducting a retrospective study between France and Switzerland to determine, on the one hand, the number of CAP cases due to Chlamydia pneumoniae confirmed by PCR, and on the other hand, to better characterize the phenotype of these patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Positive simplex or multiplex PCR for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025.
  • Availability of clinical data allowing confirmation of pneumonia diagnosis.

Exclusion criteria

  • Patient opposition to the use of medical data for research purposes.
  • Absence of pneumonia diagnosis.
  • Insufficient clinical data for analysis.

Treatment and study plan

Primary outcomes

  1. Prevalence of Chlamydia pneumoniae Among Pneumonia Cases Tested by PCR

    Time frame: January 2015 to December 2025

    Proportion of pneumonia cases with a positive simplex or multiplex PCR for Chlamydia pneumoniae among all patients who underwent respiratory PCR testing during the study period.

Secondary outcomes

  1. Clinical Severity of Chlamydia pneumoniae Pneumonia

    Time frame: From hospital admission through hospital discharge (up to 90 days)

    Distribution of patients according to outpatient management, hospitalization in a medical ward, admission to intensive care, and in-hospital mortality.

  2. Radiological Characteristics

    Time frame: Baseline (at the time of pneumonia diagnosis)

    Chest radiograph and chest computed tomography findings associated with PCR-confirmed Chlamydia pneumoniae pneumonia.

  3. Viral Co-Infection Rate

    Time frame: Baseline (at the time of PCR testing)

    Proportion of patients with concomitant viral infection identified by microbiological testing.

  4. Bacterial Co-Infection Rate

    Time frame: Baseline (at the time of PCR testing)

    Proportion of patients with concomitant bacterial infection identified by microbiological testing.

  5. Length of Hospital Stay

    Time frame: From hospital admission through hospital discharge (up to 90 days)

    Duration of hospitalization among admitted patients.

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Research Unit Coordinator Clinical Research Unit Coordinator, GHT Plaine de France Clinical

CONTACT

[email protected]

+33 1 42 35 61 40 ext. 6962

Yacine Tandjaoui-Lambiotte, Principal Investigator

CONTACT

[email protected]

+33 1 42 35 61

Sponsors and collaborators

Lead sponsor

Centre Hospitalier de Saint-Denis

Other

Registry information

Official study title

Prevalence and Phenotyping of Chlamydia Pneumoniae Infections Among Pnuemonias Tested With Simplex and Multiplex PCR

Acronym: CHLAMPAC

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jul 1, 2026
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.